Indegene Limited has announced the completion of an amalgamation involving two of its step-down subsidiaries in Canada, effective January 01, 2026. The healthcare services company disclosed this corporate restructuring under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Amalgamation Details

The amalgamation involves Indegene Aptilon Services, Inc. and Trilogy Writing & Consulting Inc. (formerly known as Trilogy Writing and Consulting ULC Canada), both 100% held by Indegene, Inc. USA, which is a wholly owned subsidiary of Indegene Limited. The combined entity has been formed as Indegene Healthcare Canada Inc.

Financial Projections

The company has provided projected revenue figures for the amalgamating entities. The combined operations are expected to generate significant revenue in the Canadian market.

Business Operations

The amalgamating entities operate in complementary areas within the healthcare sector. Trilogy specializes in medical writing and regulatory documentation services for pharmaceutical and life-science industries. Indegene focuses on digital-first life-sciences commercialization, providing technology-enabled services to support biopharmaceutical and medical-device companies in bringing therapies to market and engaging healthcare professionals and patients.

Strategic Impact

This internal restructuring represents a strategic consolidation of Indegene's Canadian operations under a unified corporate structure. The amalgamation is classified as a related party transaction conducted without any impact on the shareholding pattern of the listed entity. The move aligns with the company's efforts to streamline its international subsidiary operations and enhance operational efficiency in the Canadian healthcare market.

Indegene Limited has announced the approval of Restricted Stock Unit (RSU) grants under its RSU 2020 Plan. The company's Nomination and Remuneration Committee approved the grants on December 31, 2025, as part of its employee compensation strategy.

RSU Grant Details

The committee has approved grants of 5,08,368 RSUs to eligible employees of the company. These grants are structured in compliance with SEBI (Share Based Employee Benefits) Regulations, 2021.

Vesting Schedule and Exercise Terms

The RSU grants follow a structured four-year vesting schedule designed to retain talent and align employee interests with company performance:

• Year 1: 25% of granted options vest after completion of one year from grant date
• Year 2: 25% of granted options vest after completion of two years from grant date
• Year 3: 25% of granted options vest after completion of three years from grant date
• Year 4: 25% of granted options vest after completion of four years from grant date

Employees will have a maximum exercise period of 75 days from the respective vesting date of each tranche to exercise their options.

Regulatory Compliance

The disclosure has been made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The announcement also complies with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

The company has made the relevant information available on its official website at https://www.indegene.com/ for stakeholder reference. Company Secretary and Compliance Officer Srishti Ramesh Kaushik signed the regulatory filing on behalf of Indegene Limited.